electroCore Begins Enrollment for PTSD Clinical Study
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 07 2026
0mins
Should l Buy ECOR?
electroCore announced the enrollment of the first eight patients in a clinical study being conducted by Acacia Clinics in collaboration with the Vagus Nerve Society. As previously announced, the study is designed to evaluate the safety and effectiveness of electroCore's gammaCore non-invasive vagus nerve stimulation device as an adjunctive treatment for symptoms associated with PTSD. The study is expected to enroll up to 40 adult participants and will assess outcomes over a 12-week treatment period.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ECOR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ECOR
Wall Street analysts forecast ECOR stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 6.310
Low
12.00
Averages
15.00
High
18.00
Current: 6.310
Low
12.00
Averages
15.00
High
18.00
About ECOR
electroCore, Inc. is a commercial stage bioelectronic medicine and wellness company focused on improving health through its non-invasive vagus nerve stimulation (nVNS) technology platform and related product offerings. The Company’s portfolio also includes Quell, a wearable, app and cloud-enabled neuromodulation platform that is indicated for the treatment of fibromyalgia symptoms and lower-extremity chronic pain. Its product categories include handheld, personal use medical devices for the management and treatment of certain medical conditions such as primary headaches, and handheld, personal use consumer products. Its products include gammaCore, Quell Fibromyalgia, Truvaga and TAC-STIM. Its gammaCore Sapphire is a prescription medical device that is used for a variety of primary headache conditions. Truvaga is a personal-use consumer electronics general wellness product that does not require a prescription and is available direct-to-consumer from electroCore at www.truvaga.com.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
electroCore CEO Announces Retirement and New Leadership Appointments
- Leadership Transition: electroCore CEO Daniel Goldberger announced his retirement effective April 1, 2026, marking a pivotal shift in the company's financial and commercial strategy, with CFO Joshua Lev appointed as Interim President to ensure stability during the leadership transition.
- Strong Financial Performance: The company reported fourth-quarter 2025 revenue of $9.2 million, a 31% year-over-year increase, with full-year revenue reaching $32 million, a 27% growth over 2024, indicating sustained market demand for non-invasive pain therapeutics.
- Optimistic Outlook: Management expects revenue for 2026 to continue growing at approximately 30%, although detailed guidance is not provided due to the leadership transition; however, third-quarter activities suggest ongoing product acceptance in the market.
- Product Expansion Plans: The company plans to launch Quell Relief for lower extremity pain in 2026 and is developing next-generation mobile applications for both Truvaga and Quell, aiming to further expand the applications of its non-invasive neuromodulation platform.
See More
electroCore (ECOR) Q4 2025 Earnings Transcript
See More
ElectroCore Releases 2026 Financial Outlook with Revenue Growth Guidance
- Earnings Beat: ElectroCore reported a FY GAAP EPS of -$1.65, beating expectations by $0.07, indicating an improvement in financial performance despite still being in a loss position.
- Significant Revenue Growth: The company's FY 2023 revenue reached $32.02 million, reflecting a 27.2% year-over-year increase and surpassing market expectations by $70,000, demonstrating sustained demand for its neuromodulation platform.
- Positive 2026 Outlook: ElectroCore anticipates approximately 30% revenue growth in 2026 compared to 2025, showcasing confidence in future market opportunities that may attract more investor interest.
- Market Assessment Improvement: According to Seeking Alpha's Quant Rating, ElectroCore's revenue forecast for 2025 is between $31.8 million and $32 million, further validating market recognition of its business evolution and strategic priorities.
See More
ElectroCore Set to Announce FY Earnings Results
- Earnings Announcement: ElectroCore (ECOR) is scheduled to release its FY earnings report on March 19th after market close, with investors keenly awaiting the results to gauge the company's future growth prospects.
- Earnings Expectations: The consensus EPS estimate stands at -$0.39, reflecting a significant year-over-year improvement of 75.5%, indicating the company's efforts to enhance profitability.
- Revenue Projections: The consensus revenue estimate is $31.95 million, representing a 26.9% year-over-year increase, showcasing ElectroCore's growth potential in its neuromodulation platform business.
- Historical Performance Review: Over the past year, ElectroCore has not beaten EPS estimates at all, while it has exceeded revenue estimates 25% of the time, suggesting a relative stability in revenue growth despite challenges in profitability.
See More
electroCore (ECOR) Projects 2025 Revenue Between $31.8M and $32M
- Revenue Guidance: electroCore anticipates 2025 revenue between $31.8M and $32M, slightly below the consensus of $31.81M, indicating a cautious outlook on future growth.
- Q4 Growth Projection: The company expects Q4 2025 revenue to be between $9M and $9.2M, representing approximately 30% growth over Q4 2024, suggesting strengthening competitive positioning in the market.
- Cash Position: By the end of 2025, electroCore expects to have approximately $11.6M in cash, down from about $13.2M as of September 30, 2025, reflecting pressure from expansion and investment expenditures.
- Market Reaction: ECOR shares fell 0.62% in premarket trading to $7.0957, indicating investor caution regarding the revenue outlook.
See More
ElectroCore Increases 2025 Revenue Forecast to $32.5M Amid Enhanced Investments and Strategic Growth
Management Strategy: Dr. Thomas Errico highlighted a strategic shift towards growth through targeted investments, acquisitions, and partnerships, focusing on expanding product offerings and enhancing shareholder value while deferring profitability.
Financial Performance: The company reported a record revenue of $8.7 million for Q3 2025, a 33% increase year-over-year, with strong gross margins of 86%, driven by prescription device sales and growth in the VA hospital system.
Outlook and Guidance: CEO Daniel Goldberger raised the full-year revenue guidance to $31.5 million to $32.5 million, projecting a cash balance of approximately $10.5 million by year-end and aiming for positive adjusted EBITDA in the second half of 2026.
Risks and Challenges: Management acknowledged ongoing litigation and the impact of macroeconomic factors on revenue, emphasizing that continued investments in sales and R&D may delay near-term profitability but are essential for long-term growth.
See More
electroCore CEO Announces Retirement and New Leadership Appointments
- Leadership Transition: electroCore CEO Daniel Goldberger announced his retirement effective April 1, 2026, marking a pivotal shift in the company's financial and commercial strategy, with CFO Joshua Lev appointed as Interim President to ensure stability during the leadership transition.
- Strong Financial Performance: The company reported fourth-quarter 2025 revenue of $9.2 million, a 31% year-over-year increase, with full-year revenue reaching $32 million, a 27% growth over 2024, indicating sustained market demand for non-invasive pain therapeutics.
- Optimistic Outlook: Management expects revenue for 2026 to continue growing at approximately 30%, although detailed guidance is not provided due to the leadership transition; however, third-quarter activities suggest ongoing product acceptance in the market.
- Product Expansion Plans: The company plans to launch Quell Relief for lower extremity pain in 2026 and is developing next-generation mobile applications for both Truvaga and Quell, aiming to further expand the applications of its non-invasive neuromodulation platform.
See More
electroCore (ECOR) Q4 2025 Earnings Transcript
See More
ElectroCore Releases 2026 Financial Outlook with Revenue Growth Guidance
- Earnings Beat: ElectroCore reported a FY GAAP EPS of -$1.65, beating expectations by $0.07, indicating an improvement in financial performance despite still being in a loss position.
- Significant Revenue Growth: The company's FY 2023 revenue reached $32.02 million, reflecting a 27.2% year-over-year increase and surpassing market expectations by $70,000, demonstrating sustained demand for its neuromodulation platform.
- Positive 2026 Outlook: ElectroCore anticipates approximately 30% revenue growth in 2026 compared to 2025, showcasing confidence in future market opportunities that may attract more investor interest.
- Market Assessment Improvement: According to Seeking Alpha's Quant Rating, ElectroCore's revenue forecast for 2025 is between $31.8 million and $32 million, further validating market recognition of its business evolution and strategic priorities.
See More
ElectroCore Set to Announce FY Earnings Results
- Earnings Announcement: ElectroCore (ECOR) is scheduled to release its FY earnings report on March 19th after market close, with investors keenly awaiting the results to gauge the company's future growth prospects.
- Earnings Expectations: The consensus EPS estimate stands at -$0.39, reflecting a significant year-over-year improvement of 75.5%, indicating the company's efforts to enhance profitability.
- Revenue Projections: The consensus revenue estimate is $31.95 million, representing a 26.9% year-over-year increase, showcasing ElectroCore's growth potential in its neuromodulation platform business.
- Historical Performance Review: Over the past year, ElectroCore has not beaten EPS estimates at all, while it has exceeded revenue estimates 25% of the time, suggesting a relative stability in revenue growth despite challenges in profitability.
See More
electroCore (ECOR) Projects 2025 Revenue Between $31.8M and $32M
- Revenue Guidance: electroCore anticipates 2025 revenue between $31.8M and $32M, slightly below the consensus of $31.81M, indicating a cautious outlook on future growth.
- Q4 Growth Projection: The company expects Q4 2025 revenue to be between $9M and $9.2M, representing approximately 30% growth over Q4 2024, suggesting strengthening competitive positioning in the market.
- Cash Position: By the end of 2025, electroCore expects to have approximately $11.6M in cash, down from about $13.2M as of September 30, 2025, reflecting pressure from expansion and investment expenditures.
- Market Reaction: ECOR shares fell 0.62% in premarket trading to $7.0957, indicating investor caution regarding the revenue outlook.
See More
ElectroCore Increases 2025 Revenue Forecast to $32.5M Amid Enhanced Investments and Strategic Growth
Management Strategy: Dr. Thomas Errico highlighted a strategic shift towards growth through targeted investments, acquisitions, and partnerships, focusing on expanding product offerings and enhancing shareholder value while deferring profitability.
Financial Performance: The company reported a record revenue of $8.7 million for Q3 2025, a 33% increase year-over-year, with strong gross margins of 86%, driven by prescription device sales and growth in the VA hospital system.
Outlook and Guidance: CEO Daniel Goldberger raised the full-year revenue guidance to $31.5 million to $32.5 million, projecting a cash balance of approximately $10.5 million by year-end and aiming for positive adjusted EBITDA in the second half of 2026.
Risks and Challenges: Management acknowledged ongoing litigation and the impact of macroeconomic factors on revenue, emphasizing that continued investments in sales and R&D may delay near-term profitability but are essential for long-term growth.
See More
